|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4098 USD | +0.81% |
|
+0.94% | -55.99% |
| 10/04 | Jaguar Health, Inc., Q4 2025 Earnings Call, Apr 10, 2026 | |
| 07/04 | Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 43.35L | 1.2Cr | 97.61L | 1.17Cr | 1.15Cr | |||||
Total Revenues | 43.35L | 1.2Cr | 97.61L | 1.17Cr | 1.15Cr | |||||
Cost of Goods Sold, Total | 23.33L | 20.19L | 20.37L | 19.55L | 37.74L | |||||
Gross Profit | 20.02L | 99.37L | 77.24L | 97.34L | 77.37L | |||||
Selling General & Admin Expenses, Total | 2.6Cr | 2.67Cr | 2.3Cr | 2.4Cr | 2.79Cr | |||||
R&D Expenses | 1.51Cr | 1.76Cr | 1.86Cr | 1.65Cr | 2.5Cr | |||||
Other Operating Expenses, Total | 4.11Cr | 4.44Cr | 4.16Cr | 4.06Cr | 5.28Cr | |||||
Operating Income | -3.91Cr | -3.44Cr | -3.39Cr | -3.08Cr | -4.51Cr | |||||
Interest Expense, Total | -84.21L | -1.27Cr | -63.82L | -2L | -67T | |||||
Net Interest Expenses | -84.21L | -1.27Cr | -63.82L | -2L | -67T | |||||
Income (Loss) On Equity Invest. | - | - | - | - | - | |||||
Currency Exchange Gains (Loss) | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | -27.18L | 9L | -49.25L | -94.34L | -62.23L | |||||
EBT, Excl. Unusual Items | -5.02Cr | -4.62Cr | -4.52Cr | -4.05Cr | -5.14Cr | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Asset Writedown | - | - | -4L | - | - | |||||
In Process R&D Expenses | - | - | - | - | -8L | |||||
Insurance Settlements | - | - | - | - | - | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | -23.87L | -21.87L | 36.97L | 12.45L | -17.99L | |||||
EBT, Incl. Unusual Items | -5.26Cr | -4.84Cr | -4.19Cr | -3.93Cr | -5.4Cr | |||||
Income Tax Expense | - | - | - | - | - | |||||
Earnings From Continuing Operations | -5.26Cr | -4.84Cr | -4.19Cr | -3.93Cr | -5.4Cr | |||||
Net Income to Company | -5.26Cr | -4.84Cr | -4.19Cr | -3.93Cr | -5.4Cr | |||||
Minority Interest | - | 9L | 6L | 8L | 6L | |||||
Net Income - (IS) | -5.26Cr | -4.75Cr | -4.13Cr | -3.85Cr | -5.34Cr | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | 1L | |||||
Net Income to Common Incl Extra Items | -5.26Cr | -4.75Cr | -4.13Cr | -3.85Cr | -5.36Cr | |||||
Net Income to Common Excl. Extra Items | -5.26Cr | -4.75Cr | -4.13Cr | -3.85Cr | -5.36Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | - | - | -2.69T | -130.69 | -22.97 | |||||
Basic EPS - Continuing Operations | - | - | -2.69T | -130.69 | -22.97 | |||||
Basic Weighted Average Shares Outstanding | - | - | 15.38T | 3L | 23.32L | |||||
Net EPS - Diluted | - | - | -2.69T | -130.69 | -22.97 | |||||
Diluted EPS - Continuing Operations | - | - | -2.69T | -130.69 | -22.97 | |||||
Diluted Weighted Average Shares Outstanding | - | - | 15.38T | 3L | 23.32L | |||||
Normalized Basic EPS | - | - | -1.8T | -83.36 | -13.53 | |||||
Normalized Diluted EPS | - | - | -1.8T | -83.36 | -13.53 | |||||
Supplemental Items | ||||||||||
EBITDA | -3.74Cr | -3.24Cr | -3.19Cr | -2.89Cr | -4.32Cr | |||||
EBITA | -3.74Cr | -3.26Cr | -3.19Cr | -2.89Cr | -4.32Cr | |||||
EBIT | -3.91Cr | -3.44Cr | -3.39Cr | -3.08Cr | -4.51Cr | |||||
EBITDAR | -3.71Cr | -3.18Cr | -3.1Cr | -2.81Cr | -4.27Cr | |||||
Total Revenues (As Reported) | - | 1.2Cr | - | 1.17Cr | 1.15Cr | |||||
Effective Tax Rate - (Ratio) | - | - | - | - | - | |||||
Current Domestic Taxes | - | - | - | - | - | |||||
Total Current Taxes | - | - | - | - | - | |||||
Deferred Domestic Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | - | - | - | - | - | |||||
Normalized Net Income | -3.14Cr | -2.79Cr | -2.77Cr | -2.46Cr | -3.16Cr | |||||
Interest on Long-Term Debt | 84.21L | 1.27Cr | 63.82L | 4L | 600 | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 34.15L | 35.96L | 19.03L | 24.07L | 27.44L | |||||
Selling and Marketing Expenses | 88.94L | 88.37L | 64.6L | 76.92L | 92.35L | |||||
General and Administrative Expenses | 1.68Cr | 1.72Cr | 1.57Cr | 1.55Cr | 1.81Cr | |||||
Research And Development Expense From Footnotes | 1.51Cr | 1.76Cr | 1.86Cr | 1.65Cr | 2.58Cr | |||||
Net Rental Expense, Total | 3L | 6L | 9L | 8L | 5L | |||||
Imputed Operating Lease Interest Expense | 8L | 19.94L | 12.45L | 41.01T | 6.84T | |||||
Imputed Operating Lease Depreciation | -6L | -13.65L | -4L | 8L | 5L | |||||
Stock-Based Comp., COGS (Total) | - | - | - | - | - | |||||
Stock-Based Comp., R&D Exp. (Total) | 13.19L | 12.63L | 10.44L | 7L | 3L | |||||
Stock-Based Comp., S&M Exp. (Total) | 3L | 3L | 2L | 1L | 1L | |||||
Stock-Based Comp., G&A Exp. (Total) | 23.36L | 17.88L | 9L | 8L | 5L | |||||
Stock-Based Comp., Other (Total) | 16T | 8L | 2L | 9T | - | |||||
Total Stock-Based Compensation | 39.9L | 41.41L | 22.83L | 16.5L | 8L |
- Stock Market
- Equities
- JAGX Stock
- Financials Jaguar Health, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















